Skip to main content Skip to search Skip to main navigation

ICH: Final Q3D (R2) Guideline on Elemental Impurities

ICH Q3D (R2) has reached Step 4 of the ICH-Process and will now be distributed to the Member States for implementation. The revision (R2) focused on

  • the establishment of limits for elemental impurities by the dermal route of exposure, summarized in a new Appendix 5 Limits for Elemental Impurities by the Cutaneous and Transcutaneous Route
  • and error corrections of the PDEs for Silver (oral), Gold (oral, parenteral and inhalation) and Nickel (inhalation).

The newly established PDEs:

  • The corrected parenteral PDE for Silver is 15 μg/day.
  • The corrected PDE of Gold by oral, parenteral or inhalation routes is identified as 300, 300, 3 μg/day.
  • The corrected PDE of Nickel by inhalation is now listed with 6 μg/day.

For more details please refer to the Guideline for elemental impurities Q3D (R2), which was adopted on 26 April 2022 by the Regulatory Members of the ICH.


Source:

ICH: Quality Guidelines

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EU: Strengthened Cooperation with WHO on Pandemic Preparedness

EU: Strengthened Cooperation with WHO on Pandemic Preparedness

“Today public health faces a new kind of challenge: speed. Diseases move faster and are more unpredictable than ever, racing across borders and continents.”, said Hadja Lahbib, Commissioner for Equality, Preparedness and Crisis Management, upon signing an EU4Health contribution agreement worth over 4 million euros with the World Health Organisation’s (WHO) Hub for Pandemic and Epidemic Intelligence in Berlin on 24 July 2026.

Read more
PIC/S: Revised Recommendations on Qualification and Validation

PIC/S: Revised Recommendations on Qualification and Validation

PIC/S has published a fundamentally revised version of its “Recommendations on Qualification and Validation” (PI 006-4). The new document was issued on 30 July 2026, will enter into force on 1 October 2026, and replaces the 2007 edition. The revised document has been expanded from 26 to 49 pages.
Read more
Smart Strategies for Handling Indirect Product Contact Components

Smart Strategies for Handling Indirect Product Contact Components

Aseptic filling processes: Handling indirect product contact parts in compliance with the revised Annex 1 of the EU GMP Guide.
Read more
How do Components like Filling Needles and Laminarisators Affect First Air Integrity?

How do Components like Filling Needles and Laminarisators Affect First Air Integrity?

Here's the answer:
Read more
Swissmedic: Implementation of New EU GMP Implementing Regulations for Veterinary Medicinal Products

Swissmedic: Implementation of New EU GMP Implementing Regulations for Veterinary Medicinal Products

The new EU Implementing Regulations on GMP requirements for veterinary medicinal products and active substances will not be automatically transposed into the Swiss Medicinal Products Licensing Ordinance (MPLO) on 16 July 2026. Swissmedic has confirmed that, although the structure of the new EU legislation has changed, the underlying GMP requirements remain largely unchanged.
Read more
EU: Annexes 4 and 5 no Longer Included in the EU GMP Guide

EU: Annexes 4 and 5 no Longer Included in the EU GMP Guide

Following the entry into application of Commission Implementing Regulations (EU) 2025/2091 and (EU) 2025/2154 on the principles and guidelines of Good Manufacturing Practice (GMP) for veterinary medicinal products and active substances for veterinary medicinal products on 16 July 2026, the European Commission removed Annexes 4 and 5 from the EU GMP Guide.
Read more
Previous
Next